news flash·2025-07-18 03:02Core Viewpoint - Nomura expects BeiGene (06160.HK) to achieve its full-year sales and operating profit guidance, raising the target price to HKD 209.92 [1] Financial Performance - The company is projected to report a 33% year-on-year increase in Q2 revenue to USD 1.2 billion, in line with market expectations [1] - Gross margin is anticipated to rise by 0.3% year-on-year to 85.4%, with quarterly net profit expected to be USD 55 million, compared to a loss of USD 120 million in the same quarter last year [1] - For the second half of the year, revenue is expected to increase by 37% year-on-year to USD 2.9 billion, benefiting from the continued global sales growth of BeiGene's products [1] Future Outlook - The company is expected to record a profit of USD 119 million in the second half of the year [1] - Full-year revenue is projected to be between USD 4.9 billion and USD 5.3 billion, indicating a strong likelihood of meeting the annual sales and operating profit guidance [1] - Nomura has maintained a "Buy" rating on BeiGene's H-shares and has adjusted its revenue and profit forecasts for the company upwards by 2.1% and 2%, respectively [1]